Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) fell 7.5% during trading on Tuesday . The stock traded as low as $14.93 and last traded at $14.95. 205,629 shares traded hands during mid-day trading, an increase of 310% from the average session volume of 50,104 shares. The stock had previously closed at $16.16.
Neoleukin Therapeutics Stock Up 1.7%
The stock has a market capitalization of $188.81 million, a P/E ratio of -6.46 and a beta of 1.11. The company has a 50-day moving average price of $17.60 and a two-hundred day moving average price of $17.05.
Neoleukin Therapeutics Company Profile
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Recommended Stories
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
